Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza

Molecular Therapy — Nucleic Acids 2026 Open access

Read full text
Authors: Mai N. Vu, Jessica A. Neil, Charley Mackenzie-Kludas, Andrew Kelly, Hyon‐Xhi Tan, Kanta Subbarao, Wen Shi Lee, Adam K. Wheatley
DOI: 10.1016/j.omtn.2026.102873
Cited by: 2
References: 30

Abstract

and compromised protective capacity against SARS-CoV-2 Omicron BA.1 infection. In contrast, mRNA/LNP delivery of a neutralizing mAb conferred superior protection against lethal influenza challenge compared to equivalent recombinant protein doses. Overall, mRNA/LNP delivery comprises a feasible and attractive pathway to speed the development and deployment of antiviral antibodies. However, optimization of LNP formulation, dosing, and administration routes is required to maximize protective potential.

Fields of Study & Subjects

RNA Interference and Gene Delivery Advanced Drug Delivery Systems Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
Molecular Therapy — Nucleic Acids
Publisher
Elsevier BV
Volume
37
Issue
2
Pages
102873–102873
Publication date
26 February 2026
Language
EN